Association of 32-bp deletion polymorphism and promoter methylation of PTEN and hepatitis C virus induced hepatocellular carcinoma.
Association of 32-bp deletion polymorphism and promoter methylation of PTEN and hepatitis C virus induced hepatocellular carcinoma. Br J Biomed Sci. 2019 May 21; Authors: Badawy AA, El-Rabat A, Elshazly TA, Ali SA, Alruwaili AM, Gad DF, Dawoud MG, Elmasry EE, Zaki ME PMID: 31109254 [PubMed - as supplied by publisher]
CONCLUSIONS: Sofosbuvir may be used as an option for treatment against YFV until other drugs are identified and approved for human use. These results offer insights into the role of nonstructural protein 5 (NS5) in YFV inhibition and suggest that nonstructural proteins may be explored as drug targets for YFV treatment. PMID: 31594756 [PubMed - as supplied by publisher]
virus (HCV) is a major public health problem and a leading cause of chronic liver disease. Over 150 million people worldwide have chronic HCV infection and are at risk of developing its life-threatening complications. Acute infection is usually asymptomatic, with most patients unaware that they have contracted the virus. Some patients clear the virus spontaneously, but most become chronic carriers. If carriers are identified, they can be treated with antiviral therapy, the main goal being prevention of cirrhosis, liver failure and hepatocellular carcinoma by eradicating the virus.
A nationwide cohort study examined changes in risk of hepatocellular carcinoma after hepatitis C virus eradication among veterans.
Abstract BACKGROUND: Chronic hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. OBJECTIVE: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/daclatasvir versus sofosbuvir/ledipasvir for treatment of non-cirrhotic naïve patients for 12 weeks in...
ute;s PL, Nuño J Abstract From the beginning of liver transplant implementation, biliary anastomosis has been considered its weakness. An anastomotic bile leak is the most frequent cause of bile in the peritoneum (choleperitoneum) after liver transplant but not the only one. Here, we report a 58-year-old man with hepatitis C virus-related cirrhosis who had orthotopic liver transplant due to presence of hepatocellular carcinoma.During the immediate postoperative period, bile leakwas diagnosed on trans-Kehr cholangiography. Contrast extravasation was observed on the graft's cystic duct, and no contrast flow i...
lay F Abstract Introduction: Liver cirrhosis (20-25%), hepatocellular carcinoma (1.5-3%), insulin resistance (30-40%) and type 2 diabetes (25-30%) are common complications in patients with chronic hepatitis C virus (HCV) infection; however, data are missing from Hungary. Aim: To determine the prevalence of diabetes and insulin resistance in Hungarian HCV patients; to evaluate treatment-induced metabolic changes in relation to diabetes/insulin resistance and virological response and to perform a sustained follow-up for hepatocellular carcinoma detection. Method: We enrolled 150 Hungarian HCV genotype 1 patients (me...
Hepatitis C virus (HCV) is the primary etiologic agent of liver cirrhosis or hepatocellular carcinoma. HCV elevated infection rates are mostly due to the lack of an accurate and accessible screening and diagnosis, especially in low- and middle-income countries. Conventional HCV diagnostic algorithm consists of a serological test followed by a nucleic acid test. This sequence of tests is time consuming and not affordable for low-resource settings. Nanotechnology have introduced new promising tests for the diagnose of infectious diseases.
With the availability of direct acting antivirals (DAA) for hepatitis C virus (HCV) infection, alcoholic liver disease (ALD) has evolved as the leading indication for listing and receipt of liver transplantation (LT) followed by non-alcoholic steatohepatitis and HCV infection. However, data are limited on etiology specific trends on listings and need for LT for hepatocellular carcinoma (HCC).
CONCLUSIONS Together, these results suggest that FIB-4 is an appropriate diagnostic indicator of liver cirrhosis and HCC in chronic HCV patients in China. PMID: 31558693 [PubMed - in process]
Authors: Ndom P Abstract Hepatocellular carcinoma is a common cancer in Africa. The risk factors are well known and avoidable in most cases (hepatitis B, hepatitis C, aflatoxin and alcohol). Vaccination against hepatitis B and the fight against aflatoxin are efficient contributions to the fight against liver cancer. The costly nature of these measures in Africa is an impediment to the fight against liver cancer in Africa. PMID: 31552123 [PubMed]